Carrie Brownstein MD
Vice President, Clinical Development
Join to View Full Profile
Columbia University Department Pediatrics3959 BroadwayNew York, NY 10032
Phone+1 212-927-3214
Fax+1 212-544-1974
Dr. Brownstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1999 - 2002- New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 1996 - 1999
Tufts University School of MedicineClass of 1996
Certifications & Licensure
NY State Medical License 1997 - 2027
American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 3 citationsThe 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.Sarah A. Holstein, Nizar J. Bahlis, P. Leif Bergsagel, Manisha Bhutani, Niccolo Bolli
Transplantation and Cellular Therapy. 2021-10-01 - 47 citationsA Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher, Albiruni Ryan Abdul Razak, Katherine Van Loon
Clinical Cancer Research. 2016-03-15 - 113 citationsRandomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Sma...Suresh S. Ramalingam, David R. Spigel, David Y. Chen, Martin Steins, Jeffrey A. Engelman
Journal of Clinical Oncology. 2011-12-01
Abstracts/Posters
- Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized...Carrie Brownstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...Carrie Brownstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermedi...Carrie Brownstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
- Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational UpdatesNovember 9th, 2022
- Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with PfizerOctober 24th, 2022
Cellectis Reports Preliminary Results from Its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual MeetingDecember 5th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
